Invesco Dorsey Wright Healthcare Momentum ETFPTH

Invesco’s Dorsey Wright Healthcare Momentum ETF (PTH) has gained attention for its focus on high-momentum healthcare stocks, but the fund’s reality often diverges from its marketing pitch. As of July 2026, PTH holds 40 securities, with its top 10 positions accounting for 42% of total assets. The largest holdings include UnitedHealth Group (9.2%), Johnson & Johnson (7.8%), and Pfizer (6.5%), according to Invesco’s official disclosures. While the fund’s prospectus emphasizes a "rigorous momentum selection process," the holdings largely mirror large-cap healthcare leaders rather than niche innovators.

PTH charges an expense ratio of 0.55%, which Invesco defends as "competitive" in its marketing materials. However, this fee is higher than many broad-market ETFs, despite PTH’s concentrated approach. The fund’s tracking methodology relies on the Dorsey Wright Healthcare Momentum Index, which rebalances quarterly to favor stocks with the strongest price performance over the prior 12 months. This strategy can lead to periods of lag if momentum trends reverse, as seen during the healthcare sector’s 8% drawdown in Q2 2026.

Recent filings show PTH’s assets under management (AUM) have grown to $1.2 billion, though liquidity remains constrained. The ETF’s average daily trading volume is approximately 200,000 shares, raising concerns about slippage during volatile periods. Invesco’s own risk disclosures note that "liquidity may be limited" for certain holdings, particularly smaller names in the portfolio’s bottom quartile. Despite this, the issuer continues to market PTH as a "core holding" for healthcare exposure, a claim that may overstate its diversification benefits.

Chart watchers note that PTH has relative strength the S&P 500 Healthcare Index by 3.4% year-to-date, though its volatility has also been 20% higher. The fund’s 12-month total return of 18.6% aligns closely with its benchmark index, suggesting the momentum strategy has added minimal alpha after fees. The source directs readers to upcoming rebalancing dates, as the fund’s quarterly adjustments can lead to significant turnover and potential tax inefficiencies.